R&D Trends

RaNA acquires Shire’s messenger RNA platform

Thursday, January 5, 2017

RaNA Therapeutics, a leader in the discovery and development of a new class of medicines that target RNA, has announced the acquisition of the MRT platform, an mRNA therapy platform, developed by subsidiaries of Shire. In addition, Shire’s former MRT employees, the group focused on the development of this technology since 2008, have joined RaNA to continue to advance the platform with lead programs in cystic fibrosis (CF) and urea cycle disorders (UCD).

[Read More]

Sanofi Pasteur, Merck & Co end joint vaccines business in Europe

Thursday, January 5, 2017

Sanofi and its vaccines global business unit Sanofi Pasteur confirmed the end of their vaccine joint-venture with MSD (known as Merck & Co., in the United States and Canada), Sanofi Pasteur MSD (SPMSD). Sanofi Pasteur and MSD will separately pursue their own vaccine strategies in Europe, integrating their respective European vaccines business into their operations. The change in operations took effect January 1, 2017.

[Read More]

Vifor, ChemoCentryx expand kidney health alliance to include renal diseases

Tuesday, January 3, 2017

Vifor Pharma, a company of the Galenica Group, and ChemoCentryx have announced the expansion of their existing kidney health alliance to include the development and commercialization of CCX140, an orally-administered inhibitor of the chemokine receptor known as CCR2, for renal diseases. CCX140 has previously completed a successful phase II clinical trial in patients with diabetic kidney disease.

[Read More]

Eisai, Keio University to establish dementia research site

Monday, January 2, 2017

Eisai and Keio University have entered into a new joint research agreement for the discovery and development of new drugs targeting dementia. For this collaborative research, a research lab will be established, and researchers from Eisai and Keio University will work together to identify and validate novel drug targets and biomarkers that could potentially lead to the development of new therapeutics and preventive medicines for dementia.

[Read More]

Symcel and Colzyx partner

Tuesday, December 20, 2016

Symcel, the company behind the cell-based assay tool for real-time cellular bioenergetic measurements, calScreener, has partnered with Colzyx to test 25 different new collagen VI derived antimicrobial peptides—analyzing their capability to kill bacterial growth. These newly discovered, first-in-kind peptides each have the capability to kill bacteria in different ways. The technology will be used flexibly to test each peptide independently or in combination with others.   

[Read More]

Evotec, Celgene collaboration for neurodegenerative diseases

Friday, December 16, 2016

Evotec and Celgene have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. Initial disease areas of focus will include Amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, and multiple other neurodegenerative disorders.

[Read More]

GSK opens new global vaccines R&D center in Rockville, Maryland

Tuesday, December 13, 2016

GlaxoSmithKline will inaugurate its newest global vaccines research and development (R&D) center in Rockville, Maryland, further strengthening and expanding its vaccines presence in the USA. Up to 200 new jobs will be created at the Rockville facility, with GSK investing over $50 million in the next two years to continue to develop the site with latest state-of-the-art scientific research technology and equipment.

[Read More]